FDA Cleared Blood Lead Testing System Displayed at AACC
|
By LabMedica International staff writers Posted on 27 Jul 2015 |
|
US Food and Drug Administration (FDA) 510(k) clearance has been given for a new compact, relatively low cost analyzer to quantify lead levels in blood.
The “LeadCare Plus” clinical lead analyzer from Magellan Diagnostics (Billerica, MA, USA) offers simple-to-perform lead analysis with a compact footprint that makes blood lead testing accessible and practical for labs of any size. With dimensions smaller than a laptop, single-use consumables, and electronic calibration, the system is easy to implement even in space- and resource-constrained labs. The LeadCare Plus system is based on technology developed by Magellan Diagnostics that has been in clinical use for nearly two decades.
Blood lead testing is a critical preventative service: symptoms of lead exposure are nonspecific and subclinical, so a routine blood test is often the only way to identify exposure. According to the Centers for Disease Control and Prevention (CDC), there are over half a million children just in the USA still affected with elevated blood lead levels. Without early detection, elevated blood lead levels can impair cognition, reduce IQ, and cause attention-deficit disorders.
Amy Winslow, president, Magellan Diagnostics, said, "We are pleased that the FDA has cleared the LeadCare Plus System. Our mission is to help expand access to blood lead testing by offering a solution for every setting. With our other products CLIA-waived LeadCare II for point-of-care testing and LeadCare Ultra for high throughput lab analysis, LeadCare Plus completes this offering by providing a low capital cost system that gives even small labs the opportunity to bring this test in-house."
All three products will be on display during AACC 2015 (July 26–30; Atlanta, GA, USA) Clinical Lab Expo, Booth 3254.
Related Links:
Magellan Diagnostics
American Association for Clinical Chemistry (AACC)
AACC 2015 Annual Meeting & Clinical Lab Expo
The “LeadCare Plus” clinical lead analyzer from Magellan Diagnostics (Billerica, MA, USA) offers simple-to-perform lead analysis with a compact footprint that makes blood lead testing accessible and practical for labs of any size. With dimensions smaller than a laptop, single-use consumables, and electronic calibration, the system is easy to implement even in space- and resource-constrained labs. The LeadCare Plus system is based on technology developed by Magellan Diagnostics that has been in clinical use for nearly two decades.
Blood lead testing is a critical preventative service: symptoms of lead exposure are nonspecific and subclinical, so a routine blood test is often the only way to identify exposure. According to the Centers for Disease Control and Prevention (CDC), there are over half a million children just in the USA still affected with elevated blood lead levels. Without early detection, elevated blood lead levels can impair cognition, reduce IQ, and cause attention-deficit disorders.
Amy Winslow, president, Magellan Diagnostics, said, "We are pleased that the FDA has cleared the LeadCare Plus System. Our mission is to help expand access to blood lead testing by offering a solution for every setting. With our other products CLIA-waived LeadCare II for point-of-care testing and LeadCare Ultra for high throughput lab analysis, LeadCare Plus completes this offering by providing a low capital cost system that gives even small labs the opportunity to bring this test in-house."
All three products will be on display during AACC 2015 (July 26–30; Atlanta, GA, USA) Clinical Lab Expo, Booth 3254.
Related Links:
Magellan Diagnostics
American Association for Clinical Chemistry (AACC)
AACC 2015 Annual Meeting & Clinical Lab Expo
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Urine Analyzer
respons® UDS100
New
Pipette Calibration System
Artel PCS®
Latest AACC 2015 News
- Automated Molecular Diagnostics System Presented at AACC 2015
- Portable Molecular Diagnostics System Unveiled At 2015 AACC
- Expanded Steroid Control Launched at the 2015 AACC Annual Meeting
- Innovative New Technology to Provide Plastic-Exterior Components with Glass Interior, Presented at AACC 2015
- Eco-Friendly Immunoassay Reagents Featured at AACC 2015
- Low Cost Point-of-Care DNA Amplification Test for Chlamydia Infection Demonstrated at the 2015 AACC Annual Meeting
- Inexpensive Multipurpose Point-of-Care Analyzer Unveiled at 2015 AACC Annual Meeting
- State-of-the-Art Automated Laboratory Systems Highlighted at the 2015 AACC Annual Meeting
- Siemens Showcases Multiple New IVD Solutions at AACC 2015
- New HPLC Quadruples Clinical Throughput Capabilities, Displayed at AACC 2015
- Diagnostic Test that Measures Active Renin in Hypertension Displayed at the 2015 AACC Annual Meeting
- Hair Testing May Offer Insights into Asthma-Related Complications in Pregnancy
- Two Newly Developed Tests May Better Diabetes Diagnosis and Monitoring
- CE Marking of Theranostic Monitoring Test Announced at 2015 AACC Annual Meeting
- Ebola Rapid Lateral Flow Test Previewed at the 2015 AACC Annual Meeting
- AACC: Better Quality and Patient-Friendliness Needed in Direct Testing
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Molecular Diagnostics
view channel
RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Many patients with advanced solid tumors exhaust broad DNA panel testing yet still lack biomarkers that match guideline-recommended therapies, limiting access to targeted options. Expanding molecular profiling... Read more
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microbiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read more
Pathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read more
Technology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read more
Industry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more
